Weekly Digest – November 2025 Weekly Digest – November 2025 13 November 2025: ITM announces FDA acceptance of New Drug Application (NDA) and PDUFA Date for n.c.a. 177Lu-edotreotide (ITM-11) in gastroenteropancreatic neuroendocrine tumors ITM announced that the FDA has accepted its New […]
Weekly Digest – November 2025 Weekly Digest – November 2025 10 November 2025: Avenzo Therapeutics granted Fast Track Designation for AVZO-1418, a potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate, for the treatment of patients with EGFR-mutated TKI-pretreated NSCLC Avenzo Therapeutics announced that the FDA has granted Fast Track designation to AVZO-1418, […]
Weekly Digest – November 2025 Weekly Digest – November 2025 10 November 2025: Arrivent Biopharma received FDA IND clearance for ARR-217, a CDH-17 targeted ADC ArriVent highlighted steady progress across its pipeline, including FDA IND clearance for ARR-217, a CDH17-targeted ADC […]
Weekly Digest – November 2025 Weekly Digest – November 2025 10 November 2025: Celltrion’s solid tumor ADC drug candidate CT-P73 has received approval for phase 1 clinical trials in Korea Celltrion has moved its new ADC candidate CT-P73 into domestic […]
Weekly Digest – November 2025 Weekly Digest – November 2025 07 November 2025: BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, demonstrates a median overall survival (OS) of 21.5 months in subtypes of refractory soft tissue sarcomas BioAtla shared new Phase 2 data showing that its AXL-targeting […]
Weekly Digest – November 2025 Weekly Digest – November 2025 13 November 2025: Day One to acquire Mersana Therapeutics to advance mission to bring new medicines to people of all ages with life-threatening diseases Day One Biopharmaceuticals announced a major step […]
